Bennouna, Jaafar <br/><br/>
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.  [electronic resource] 

 -  Investigational new drugs  Feb 2015 
 - 138-47 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-014-0142-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Camptothecin--administration & dosage<br/>Cetuximab<br/>Colorectal Neoplasms--drug therapy<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Indazoles<br/>Irinotecan<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Recurrence<br/>Sulfonamides--administration & dosage<br/>Topoisomerase I Inhibitors--administration & dosage<br/>Treatment Outcome